Quantifying diagnosis and treatment practices of opioid use disorder in primary care practices using chart review data

References

• National Institute on Drug Abuse. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates. Accessed September 21, 2023.
   Google Scholar
• Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm. Accessed September 21, 2023.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report. Accessed September 21, 2023.
   Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55-63–e63. doi:10.2105/AJPH.2015.302664.
   PubMed Web of Science ®Google Scholar
• Solomon KT, Bandara S, Reynolds IS, Krawczyk N, Saloner B, Stuart E, Connolly E. Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis. J Subst Abuse Treat. 2022;132:108424. doi:10.1016/j.jsat.2021.108424.
   PubMed Web of Science ®Google Scholar
• Steinberg J, Azofeifa A, Sigounas G. Mobilizing primary care to address the opioid use disorder treatment gap. Public Health Rep. 2019;134(5):456–60. doi:10.1177/0033354919863430.
   PubMed Web of Science ®Google Scholar
• Anderson JB, Martin SA, Gadomski A, Krupa N, Mullin D, Cahill A, Jenkins P. Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes. Subst Abus. 2022;43(1):222–30. doi:10.1080/08897077.2021.1931633.
   PubMed Web of Science ®Google Scholar
• Zittleman L, Curcija K, Nease DE, Fisher M, Miriam Dickinson L, Thomas JF, Espinoza A, Sutter C, Ancona J, Holtrop JS, et al. Increasing capacity for treatment of opioid use disorder in rural primary care practices. Ann Fam Med. 2022;20(1):18–23. doi:10.1370/afm.2757.
   PubMed Web of Science ®Google Scholar
• Fox AD, Masyukova M, Cunningham CO. Optimizing psychosocial support during office-based buprenorphine treatment in primary care: Patients’ experiences and preferences. Subst Abus. 2016;37(1):70–5. doi:10.1080/08897077.2015.1088496.
   PubMed Web of Science ®Google Scholar
• SAMHSA. https://www.samhsa.gov/providers-clinical-support-system-pcss. Accessed September 21, 2023.
   Google Scholar
• SAMHSA. https://www.samhsa.gov/state-targeted-response-technical-assistance-str-ta. Accessed September 21, 2023.
   Google Scholar
• Centers for Disease Control and Prevention. https://www.cdc.gov/opioids/healthcare-professionals/prescribing/guideline/at-a-glance.html. Accessed September 21, 2023.
   Google Scholar
• SAMHSA. https://store.samhsa.gov/sites/default/files/pep21-06-01-002.pdf. Accessed September 21, 2023.
   Google Scholar
• American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. American Society of Addiction Medicine, Rockville, MD; 2020. p. 95.
   Google Scholar
• Providers Clinical Support System (PCSS). https://pcssnow.org/resources/clinical-tools/. Accessed September 21, 2023.
   Google Scholar
• AAAP. Improving clinical practice with patients who have opioid use disorder (OUD): Performance in practice (PIP) activity, East Providence, RI; 2019.
   Google Scholar
• Lutgen C, Callen E, Robertson E, Clay T, Filippi MK. Implementation and evaluation of primary care team participation in opioid use disorder learning sessions. Subst Abus. 2023;44(1):51–61. doi:10.1177/08897077231174675.
   PubMed Web of Science ®Google Scholar
• Rhee TG, Rosenheck RA. Use of drug treatment services among adults with opioid use disorder: Rates, patterns, and correlates. Psychiatr Serv. 2019;70(11):992–9. doi:10.1176/appi.ps.201900163.
   PubMed Web of Science ®Google Scholar
• Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019. JAMA Netw Open. 2022;5(3):e223821. doi:10.1001/jamanetworkopen.2022.3821.
   PubMed Web of Science ®Google Scholar
• Andraka-Christou B, Capone MJ. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. Int J Drug Policy. 2018;54:9–17. doi:10.1016/j.drugpo.2017.11.021.
   PubMed Web of Science ®Google Scholar
• Saloner B, Daubresse M, Caleb Alexander G. Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Med Care. 2017;55(7):669–76. doi:10.1097/MLR.0000000000000727.
   PubMed Web of Science ®Google Scholar
• Campbell MD, Kolodner G, Spencer RA, DuPont RL. Drug test results as a predictor of retention among ­patients using buprenorphine in a comprehensive outpatient treatment program. J Addict Dis. 2016;35(4):315–24. doi:10.1080/10550887.2016.1139427.
   PubMed Web of Science ®Google Scholar
• Vassileva J, Conrod PJ. Impulsitivites and addictions: A multidimensional integrative framework informing assessment and interventions for substance use disorders. Phil Trans R Soc B. 2019;374(1766):20180137. doi:10.1098/rstb.2018.0137.
   PubMed Web of Science ®Google Scholar
• Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78–82. doi:10.1016/j.drugalcdep.2018.12.030.
   PubMed Web of Science ®Google Scholar
• SAMHSA. TIP 42: Substance use treatment for persons with co-occurring disorders, Rockville, MD; 2020.
   Google Scholar
• Czeisler MÉ, Howard ME, Rajaratnam SMW. Mental health during the COVID-19 pandemic: Challenges, populations at risk, implications, and opportunities. Am J Health Promot. 2021;35(2):301–11. doi:10.1177/0890117120983982b.
   PubMed Web of Science ®Google Scholar
• Wejnert C, Hess KL, Hall HI, Van Handel M, Hayes D, Fulton P, An Q, Koenig LJ, Prejean J, Valleroy LA, et al. Vital signs: Trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs - United States. MMWR Morb Mortal Wkly Rep. 2016;65(47):1336–42. doi:10.15585/mmwr.mm6547e1.
   PubMed Web of Science ®Google Scholar
• Suryaprasad AG, White JZ, Xu F, Eichler B-A, Hamilton J, Patel A, Hamdounia SB, Church DR, Barton K, Fisher C, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59(10):1411–9. doi:10.1093/cid/ciu643.
   PubMed Web of Science ®Google Scholar
• Ahrens K, Sharbaugh M, Jarlenski MP, Tang L, Allen L, Austin AE, Barnes AJ, Burns ME, Clark S, Zivin K, et al. Prevalence of testing for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among medicaid enrollees treated with medications for opioid use disorder in 11 states, 2016-2019. Clin Infect Dis. 2023;76(10):1793–801. doi:10.1093/cid/ciac981.
   Web of Science ®Google Scholar
• Hallgren KA, Witwer E, West I, Baldwin L-M, Donovan D, Stuvek B, Keppel GA, Mollis B, Stephens KA. Prevalence of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network. J Subst Abuse Treat. 2020;110:18–27. doi:10.1016/j.jsat.2019.11.008.
   PubMed Web of Science ®Google Scholar
• Rangachari P, Woods JL Preserving organizational resilience, patient safety, and staff retention during COVID-19 requires a holistic consideration of the psychological safety of healthcare workers. Int J Environ Res Public Health. 2020;17(12):4267. doi:10.3390/ijerph17124267.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Vanaparthy R, Atluri S, Sachdeva H, Kaye AD, Hirsch JA. COVID-19 and the opioid epidemic: Two public health emergencies that intersect with chronic pain. Pain Ther. 2021;10(1):269–86. doi:10.1007/s40122-021-00243-2.
   PubMed Web of Science ®Google Scholar
• Melnikow J, Padovani A, Miller M. Frontline physician burnout during the COVID-19 pandemic: National survey findings. BMC Health Serv Res. 2022;22(1):365. doi:10.1186/s12913-022-07728-6.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning, Silver Spring, MD; 2017.
   Google Scholar
• Tilhou AS, Dague L, Saloner B, Beemon D, Burns M. Trends in engagement with opioid use disorder treatment among medicaid beneficiaries during the COVID-19 pandemic. JAMA Health Forum. 2022;3(3):e220093. doi:10.1001/jamahealthforum.2022.0093.
   PubMedGoogle Scholar
• Samples H, Williams AR, Crystal S, Olfson M. Impact of long-term buprenorphine treatment on adverse health care outcomes in medicaid. Health Affairs. 2020;39(5):747–55. doi:10.1377/hlthaff.2019.01085.
   Web of Science ®Google Scholar
• Davis CS, Carr D. Over the counter naloxone needed to save lives in the United States. Prevent Med. 2020;130:105932. doi:10.1016/j.ypmed.2019.105932.
   PubMed Web of Science ®Google Scholar
• Collins AB, Ndoye CD, Arene-Morley D, Marshall BDL. Addressing co-occurring public health emergencies: The importance of naloxone distribution in the era of COVID-19. Int J Drug Pol. 2020;83:102872. doi:10.1016/j.drugpo.2020.102872.
   PubMed Web of Science ®Google Scholar
• Association LAaPP. Naloxone access: Summary of state laws, Washington, DC; 2023. p. 193.
   Google Scholar
• Werder K, Curtis A, Reynolds S, Satterfield J. Addressing bias and stigma in the language we use with persons with opioid use disorder: A narrative review. J Am Psychiatr Nurses Assoc. 2022;28(1):9–22. doi:10.1177/10783903211050121.
   PubMed Web of Science ®Google Scholar
• Allen B, Harocopos A, Chernick R. Substance use stigma, primary care, and the New York state prescription drug monitoring program. Behav Med. 2020;46(1):52–62. doi:10.1080/08964289.2018.1555129.
   PubMed Web of Science ®Google Scholar
• Gearing RE, Mian IA, Barber J and Ickowicz A. A methodology for conducting retrospective chart review research in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2006;15(3):126–34.
   PubMedGoogle Scholar
• Vassar M, Holzmann M. The retrospective chart review: Important methodological considerations. J Educ Eval Health Prof. 2013;10:12. doi:10.3352/jeehp.2013.10.12.
   PubMedGoogle Scholar
• Filippi MK, Callen E, Wade A, Coffman M, Westfall JM, Jabbarpour Y, Hester CM, Carroll J. COVID-19's financial impact on primary care clinicians and practices. J Am Board Fam Med. 2021;34(3):489–97. doi:10.3122/jabfm.2021.03.200502.
   Web of Science ®Google Scholar
• Singer SJ, Glassman J, Glaseroff A, Joseph GA, Jauregui A, Mulaney B, Kelly SS, Thomas S, Vilendrer S, and Tietschert MV. Impact of COVID-19 on primary care practice sites and their vulnerable patients. In The Contributions of Health Care Management to Grand Health Care Challenges 2021 Dec 6 (Vol. 20, pp. 233–271). Emerald Publishing Limited.
   Google Scholar
• Caton L, Cheng H, Garneau HC, Fisher T, Harris-Mills B, Hurley B, Newman S, McGovern MP. COVID-19 adaptations in the care of patients with opioid use disorder: A survey of California primary care clinics. J Gen Intern Med. 2021;36(4):998–1005. doi:10.1007/s11606-020-06436-3.
   PubMed Web of Science ®Google Scholar
• Gregory HM, Hill VM, Parker RW. Implications of increased access to buprenorphine for medical providers in rural areas: A review of the literature and future directions. Cureus. 2021;13(11):e19870. doi:10.7759/cureus.19870.
   PubMed Web of Science ®Google Scholar